Answers are grounded in this paper and cite their sources.
Our data demonstrated that SUMO1 modification of IGF-1R inhibited osteogenic differentiation of PDLSCs by binding to SNAI2 in high glucose environment, a key factor leading to alveolar bone loss in diabetic patients. Thus we could maximize the control of multiple downstream damage signaling factors and bring new hope for alveolar bone regeneration in diabetic patients.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: